U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H10IN3
Molecular Weight 271.091
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IOBENGUANE I-123

SMILES

c1cc(cc(c1)I)CNC(=N)N

InChI

InChIKey=PDWUPXJEEYOOTR-IUAIQHPESA-N
InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9-4

HIDE SMILES / InChI

Molecular Formula C8H10IN3
Molecular Weight 271.091
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

IOBENGUANE I-123 (AdreView®) is a radiopharmaceutical agent for gamma-scintigraphy. It is similar in structure to the antihypertensive drug guanethidine and to the neurotransmitter norepinephrine (NE). IOBENGUANE is, therefore, largely subject to the same uptake and accumulation pathways as NE. It is taken up by the NE transporter in adrenergic nerve terminals and stored in the presynaptic storage vesicles. IOBENGUANE accumulates in adrenergically innervated tissues such as the adrenal medulla, salivary glands, heart, liver, spleen, and lungs as well as tumors derived from the neural crest. By labeling IOBENGUANE with the isotope iodine 123 (I-123), it is possible to obtain scintigraphic images of the organs and tissues in which the radiopharmaceutical accumulates. IOBENGUANE I-123 (AdreView®) is indicated for use in the detection of primary or metastatic pheochromocytoma or neuroblastoma. It is also used for scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, IOBENGUANE I-123 (AdreView®) may be used to help identify patients with lower one and two-year mortality risks, as indicated by an H/M ratio ≥ 1.6.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
ADREVIEW

Approved Use

AdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for: - use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests; - scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6.

Launch Date

1.22169603E12
Diagnostic
ADREVIEW

Approved Use

AdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for: - use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests; - scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6.

Launch Date

1.22169603E12
Diagnostic
ADREVIEW

Approved Use

AdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for: - use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests; - scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6.

Launch Date

1.22169603E12
Diagnostic
ADREVIEW

Approved Use

AdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for: - use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests; - scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6.

Launch Date

1.22169603E12

Sample Use Guides

5 mL of sterile solution for intravenous injection in a single-use vial (2 mCi/mL at calibration time). For patients ≥ 16 years of age or < 16 years of age and ≥ 70 kg administer 10 mCi (370 MBq).
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:01:28 UTC 2021
Edited
by admin
on Sat Jun 26 06:01:28 UTC 2021
Record UNII
P2TH1XYZ84
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IOBENGUANE I-123
DASH  
Common Name English
3-IODOBENZYLGUANIDINE (123I)
JAN  
Common Name English
((3-(IODO-(SUP 123)I)-PHENYL)METHYL)GUANIDINE
Common Name English
(M-IODO-(SUP 123)I)-BENZYL)GUANIDINE
Common Name English
123I-MIBG
Common Name English
IOBENGUANE I 123
USP   VANDF  
Common Name English
IOBENGUANE I 123 [VANDF]
Common Name English
3-IODOBENZYLGUANIDINE (123I) [JAN]
Common Name English
IODINE (123I) IOBENGUANE
Common Name English
MIBG I-123
Common Name English
123I-METAIODOBENZYLGUANIDINE
Common Name English
METAIODOBENZYLGUANIDINE I-123
Common Name English
ANDREVIEW
Brand Name English
IOBENGUANE (123 I)
WHO-DD  
Common Name English
IOBENGUANE (123-I)
Common Name English
IOBENGUANE I 123 [USP]
Common Name English
IOBENGUANE (123 I) [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QV09IX01
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
NCI_THESAURUS C2124
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
FDA ORPHAN DRUG 226506
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
WHO-ATC V09IX01
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
FDA ORPHAN DRUG 226406
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C80094
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
DRUG CENTRAL
1448
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
EVMPD
SUB12077MIG
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
FDA UNII
P2TH1XYZ84
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
ChEMBL
CHEMBL818
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
DRUG BANK
DBSALT002469
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
LACTMED
Iobenguane I 123
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
RXCUI
1426748
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY RxNorm
EVMPD
SUB127296
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
CAS
76924-93-1
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
PUBCHEM
135326
Created by admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY